1-{[3-bromo-2-(2-trifluoromethanesulfonamidophenyl)-1-benzofuran-5-yl]methyl}-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide

• ChemBase ID: 1176
• Molecular Formular: C25H22BrF3N4O4S
• Molecular Mass: 611.4307896
• Monoisotopic Mass: 610.04972286
• SMILES: Brc1c2cc(Cn3c(c(nc3CC)C3CC3)C(=O)N)ccc2oc1c1c(NS(=O)(=O)C(F)(F)F)cccc1
• Canonical SMILES: CCc1nc(c(n1Cc1ccc2c(c1)c(Br)c(o2)c1ccccc1NS(=O)(=O)C(F)(F)F)C(=O)N)C1CC1
• InChI: InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
• InChIKey: DUEWVPTZCSAMNB-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-{[3-bromo-2-(2-trifluoromethanesulfonamidophenyl)-1-benzofuran-5-yl]methyl}-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide
• IUPAC Traditional name: 3-{[3-bromo-2-(2-trifluoromethanesulfonamidophenyl)-1-benzofuran-5-yl]methyl}-5-cyclopropyl-2-ethylimidazole-4-carboxamide
• Synonyms: Saprisartan

Database IDs

• CAS Number: 146623-69-0
• PubChem SID: 46508176; 160964638
• PubChem CID: 60921

CALCULATED PROPERTIES

JChem

• H Acceptors: 4
• H Donor: 2
• LogD (pH = 5.5): 4.1792154
• LogD (pH = 7.4): 4.3395157
• Log P: 3.3470178
• Molar Refractivity: 137.1475 cm^3
• Polarizability: 54.258743 Å^3
• Polar Surface Area: 120.22 Å^2
• Rotatable Bonds: 8
• Lipinski's Rule of Five: false
• Acid pKa: 2.2661362

ALOGPS 2.1

• Log P: 5.89
• LOG S: -4.61
• Solubility (Water): 1.51e-02 g/l

DETAILS

DrugBank - DB01347

• Drug Groups: approved
• Description: Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism.(10579749)
• Indication: Saprisartan is used in the treatment of hypertension and heart failure.
• Pharmacology: By inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.
• Affected Organisms: Humans and other mammals